Earnings Releases·Nov 12, 2026, 4:34 PM ET

CapsoVision — Third Quarter 2026 Earnings Summary

Q3 2026 revenue rose to $3.6 million from $3.5 million in the prior year period, while gross margin contracted to 49% from 54% due to higher material costs and inventory charges; net loss narrowed to $7.3 million ($0.15/share) from $7.9 million ($0.17/share) year-over-year.
The company secured FDA clearance for AI Highlights™ on September 25, 2026, with a U.S. launch scheduled for November 2, 2026, and maintains a year-end 2026 timeline for the FDA 510(k) submission of the second-generation CapsoCam Colon™.
Capital position strengthened significantly with cash and equivalents reaching $21.8 million as of September 30, 2026, driven by an $18 million registered direct offering and $1.7 million in ATM proceeds, alongside a 22% increase in total stockholders' equity to $26.4 million.
The CapsoCam Plus user base expanded to over 184,000 patients globally, and the company anticipates AI Highlights will drive sales growth with full commercial impact expected in 2027, while clinical expenses for the CapsoCam Colon pivotal study are projected to decline following enrollment completion.